Clinical Trial Update: Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study of the PARP inhibitor E7016 in combination with temozolomide for wild-type BRAF advanced melanoma (stage IV or unresectable stage III) has been te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• E7016 (E7016)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Eisai Inc. | Conditions: Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma | Phase 2 | Status: TERMINATED